PMID- 25586555
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150326
LR  - 20201001
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 6
IP  - 1
DP  - 2015 Mar
TI  - A survey of patient preferences for oral antihyperglycemic therapy in patients 
      with type 2 diabetes mellitus.
PG  - 75-84
LID - 10.1007/s13300-015-0094-2 [doi]
AB  - INTRODUCTION: Previous research has demonstrated a correlation among patient 
      preferences, dosing burden, and medication nonadherence, a well-recognized 
      challenge in type 2 diabetes mellitus (T2DM). The objective of this study was to 
      elicit preferences for alternative dosing regimens for oral antihyperglycemic 
      therapies among patients with T2DM and to quantify differences in dosing 
      preferences among patients with different characteristics. METHODS: Preferences 
      for dosing of oral antihyperglycemic drugs (OAD) were evaluated by surveying 
      patients with T2DM in the United States (US). Survey participants were adult US 
      patients with T2DM who were taking no or only 1 OAD and no injectable therapies. 
      Each patient completed a web-enabled discrete-choice experiment (DCE) including a 
      series of 8 pairs of hypothetical OAD profiles. Each profile was defined by 
      reductions in average glucose, dosing schedule (e.g., once-weekly, once-daily, or 
      twice-daily dosing), chance of mild-to-moderate gastrointestinal side effects, 
      frequency of hypoglycemia, weight change, incremental risk of congestive heart 
      failure, and cost. Each participant also answered a direct question about dosing 
      preference. Random-parameters logit was used to analyze the DCE data. 
      Prespecified subgroups were analyzed. RESULTS: Of 2,262 patients invited to 
      participate, 923 were included in the analysis (mean age 63 years, 45% male, 79% 
      white). Reducing dosing frequency was statistically significantly important to 
      patients; however, it was relatively less important than medication cost or 
      clinical outcomes. On average, patients preferred once-weekly to once-daily 
      dosing. Patients not currently taking an OAD had a stronger preference for 
      once-weekly dosing than patients on treatment (P = 0.012). Patients younger than 
      45 years had a stronger preference for weekly dosing than older patients 
      (P < 0.075). CONCLUSIONS: For younger patients and patients not currently on 
      treatment, once-weekly dosing may provide additional incentive to initiate and 
      adhere to antihyperglycemic treatment; however, additional research will be 
      required to confirm this hypothesis.
FAU - Hauber, A Brett
AU  - Hauber AB
AD  - RTI Health Solutions, 200 Park Offices Drive, PO Box 12194, Research Triangle 
      Park, NC, USA, abhauber@rti.org.
FAU - Tunceli, Kaan
AU  - Tunceli K
FAU - Yang, Jui-Chen
AU  - Yang JC
FAU - Gantz, Ira
AU  - Gantz I
FAU - Brodovicz, Kimberly G
AU  - Brodovicz KG
FAU - Alexander, Charles M
AU  - Alexander CM
FAU - Davies, Michael J
AU  - Davies MJ
FAU - Radican, Larry
AU  - Radican L
LA  - eng
PT  - Journal Article
DEP - 20150114
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC4374080
EDAT- 2015/01/15 06:00
MHDA- 2015/01/15 06:01
PMCR- 2015/01/14
CRDT- 2015/01/15 06:00
PHST- 2014/10/31 00:00 [received]
PHST- 2015/01/15 06:00 [entrez]
PHST- 2015/01/15 06:00 [pubmed]
PHST- 2015/01/15 06:01 [medline]
PHST- 2015/01/14 00:00 [pmc-release]
AID - 94 [pii]
AID - 10.1007/s13300-015-0094-2 [doi]
PST - ppublish
SO  - Diabetes Ther. 2015 Mar;6(1):75-84. doi: 10.1007/s13300-015-0094-2. Epub 2015 Jan 
      14.